Prostate-specific membrane antigen (PSMA)-targeting strategies in prostate cancer have evolved rapidly from early antibody-based approaches to highly effective diagnostic and therapeutic agents. While PSMA remains a central benchmark in metastatic disease, biological heterogeneity and therapy resistance underscore the need for continued innovation and rational combination strategies.
European Urology published a clinical update in Research Highlights on 14 Jan 2026.
The item focuses on The Discovery of Prostate-specific Membrane Antigen Ligands: The Long Road to Changes in Clinical Practice for Prostate Cancer.
Review the original article for the full source wording and details.